1-ALPHA-HYDROXYVITAMIN D-3 TREATMENT DECREASES BONE TURNOVER AND MODULATES CALCIUM-REGULATING HORMONES IN EARLY POSTMENOPAUSAL WOMEN

Citation
Jt. Chen et al., 1-ALPHA-HYDROXYVITAMIN D-3 TREATMENT DECREASES BONE TURNOVER AND MODULATES CALCIUM-REGULATING HORMONES IN EARLY POSTMENOPAUSAL WOMEN, Bone, 20(6), 1997, pp. 557-562
Citations number
41
Categorie Soggetti
Endocrynology & Metabolism
Journal title
BoneACNP
ISSN journal
87563282
Volume
20
Issue
6
Year of publication
1997
Pages
557 - 562
Database
ISI
SICI code
8756-3282(1997)20:6<557:1DTDBT>2.0.ZU;2-6
Abstract
50 Japanese women within 10 years after menopause (mean age 52.5 years ) were studied to determine the effects of 0.75 mu g of 1-alpha-hydrox yvitamin D-3 [1-alpha-(OH)D-3] with calcium (150 mg/day) (treated grou p: N = 25) and calcium only (control group: N = 25) for 12 months on b one mass and metabolism, Their L2-4 BMD measurements were 1.5 SD below the mean value of Japanese young, normal women, L2-4 BMDs increased s ignificantly in the treated group (+2.1%; p < 0.01), but decreased sig nificantly in controls (-2.1%;p < 0.01), Although serum calcium and cr eatinine remained unchanged in both groups, phosphorus levels increase d significantly in the treated group (p < 0.01), Urinary calcium/creat inine (Cr) increased in both groups, Urinary pyridinoline/Cr and deoxy pyridinoline/Cr decreased significantly in the treated group (p < 0.05 ), but not in the control group, Serum osteocalcin levels remained unc hanged in both groups, Intact parathyroid hormone levels decreased sig nificantly (p < 0.05) and calcitonin levels significantly increased in the treated group (p < 0.05), but these changes were not observed in the control group, These data clearly demonstrate that 0.75 mu g of 1- alpha-(OH)D-3 maintained bone mass by reducing bone resorption by modu lation of calcium-regulating hormones, Temporarily increased urinary c alcium excretion was observed in control group, but did not appear to be effective in modulating bone turnover. (C) 1997 by Elsevier Science Inc.